Success Metrics

Clinical Success Rate
47.4%

Based on 9 completed trials

Completion Rate
47%(9/19)
Active Trials
4(15%)
Results Posted
144%(13 trials)
Terminated
10(37%)

Phase Distribution

Ph phase_1
13
48%
Ph not_applicable
1
4%
Ph phase_2
12
44%
Ph phase_3
1
4%

Phase Distribution

13

Early Stage

12

Mid Stage

1

Late Stage

Phase Distribution27 total trials
Phase 1Safety & dosage
13(48.1%)
Phase 2Efficacy & side effects
12(44.4%)
Phase 3Large-scale testing
1(3.7%)
N/ANon-phased studies
1(3.7%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

40.9%

9 of 22 finished

Non-Completion Rate

59.1%

13 ended early

Currently Active

4

trials recruiting

Total Trials

27

all time

Status Distribution
Active(4)
Completed(9)
Terminated(13)
Other(1)

Detailed Status

Terminated10
Completed9
Withdrawn3
Active, not recruiting2
Recruiting2
unknown1

Development Timeline

Analytics

Development Status

Total Trials
27
Active
4
Success Rate
47.4%
Most Advanced
Phase 3

Trials by Phase

Phase 113 (48.1%)
Phase 212 (44.4%)
Phase 31 (3.7%)
N/A1 (3.7%)

Trials by Status

terminated1037%
active_not_recruiting27%
completed933%
recruiting27%
unknown14%
withdrawn311%

Recent Activity

4 active trials
Showing 5 of 27
completedphase_1

First in Human Study of M6223

NCT04457778
active_not_recruitingphase_1

A Phase I/II Study of Combination Immunotherapy for Advanced Cancers Including HPV-Associated Malignancies, Small Bowel, and Colon Cancers

NCT04708470
terminatedphase_1

Bintrafusp Alfa and Pimasertib for the Treatment of Patients With Brain Metastases

NCT04789668
active_not_recruitingphase_1

Hypofractionated Radiation Therapy and Bintrafusp Alfa for the Treatment of Advanced Intrahepatic Cholangiocarcinoma

NCT04708067
completedphase_3

Bintrafusp Alfa Program Rollover Study

NCT05061823
View all 27 trials

Clinical Trials (27)

Showing 20 of 27 trialsScroll for more
NCT04457778Phase 1

First in Human Study of M6223

Completed
NCT04708470Phase 1

A Phase I/II Study of Combination Immunotherapy for Advanced Cancers Including HPV-Associated Malignancies, Small Bowel, and Colon Cancers

Active Not Recruiting
NCT04789668Phase 1

Bintrafusp Alfa and Pimasertib for the Treatment of Patients With Brain Metastases

Terminated
NCT04708067Phase 1

Hypofractionated Radiation Therapy and Bintrafusp Alfa for the Treatment of Advanced Intrahepatic Cholangiocarcinoma

Active Not Recruiting
NCT05061823Phase 3

Bintrafusp Alfa Program Rollover Study

Completed
NCT05005429Phase 2

Study of the Efficacy and Safety of the Bintrafusp Alfa in Previously Treated Advanced Malignant Pleural Mesothelioma

Completed
NCT04396535Phase 2

Docetaxel With or Without Bintrafusp Alfa for the Treatment of Advanced Non-small Cell Lung Cancer

Terminated
NCT04874311Phase 2

Bintrafusp Alfa and Doxorubicin Hydrochloride in Treating Patients With Advanced Sarcoma

Recruiting
NCT02723955Phase 1

Dose Escalation and Expansion Study of GSK3359609 in Participants With Selected Advanced Solid Tumors (INDUCE-1)

Completed
NCT04220775Phase 1

Bintrafusp Alfa and Stereotactic Body Radiation Therapy for the Treatment of Recurrent or Second Primary Head and Neck Squamous Cell Cancer

Terminated
NCT03620201Phase 1

M7824 in Treating Patients With Stage II-III HER2 Positive Breast Cancer

Completed
NCT04481256Not Applicable

TGF-β And PDL-1 Inhibition in Esophageal Squamous Cell Carcinoma Combined With Chemoradiation TheRapY

Recruiting
NCT04396886Phase 2

Bintrafusp Alfa in Previously Treated Patients With R/M Non-keratinizing NPC

Completed
NCT04349280Phase 1

A Study to Evaluate the Efficacy and Safety of Bintrafusp Alfa (M7824) Monotherapy in Metastatic or Locally Advanced Urothelial Cancer

Terminated
NCT05445882Phase 2

N-803 Alone or in Combination With BN-Brachyury Vaccine or Bintrafusp Alfa (M7824) for Participants With Castration Resistant Prostate Cancer

Withdrawn
NCT04756505Phase 1

Immunotherapy (NHS-IL12 & Bintrafusp Alfa) and Radiation Therapy for the Treatment of Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer, the REINA Trial

Withdrawn
NCT04246489Phase 2

Bintrafusp Alfa Monotherapy in Platinum-Experienced Cervical Cancer

Completed
NCT03840915Phase 1

M7824 in Combination With Chemotherapy in Stage IV Non-small Cell Lung Cancer (NSCLC)

Completed
NCT04971187Phase 2

Bintrafusp Alfa With Chemotherapy for Tyrosine Kinase Inhibitor-Resistant EGFR-Mutant Non-small Cell Lung Cancer

Terminated
NCT04489940Phase 2

Bintrafusp Alfa in High Mobility Group AT-Hook 2 (HMGA2) Expressing Triple Negative Breast Cancer

Terminated

Drug Details

Intervention Type
DRUG
Total Trials
27